Bionomics Limited

ABN 53 075 582 740

ASX ANNOUNCEMENT
30 August 2010

BNC210 Data Presented at Leading European Forum

- **BNC210 is more effective than Diazepam in reducing anxiety in a rat model which mimics panic attacks in humans and lacks sedative side-effects in the model**
- **BNC210 is safe and well tolerated up to a dose of 2000mg in humans**
- **A single oral dose results in higher drug exposure levels than those required for efficacy in preclinical models and is maximal when taken after food.**

30 August 2010; Adelaide, Australia: Bionomics Limited (ASX: BNO) today announced the presentation of preclinical and clinical data for its anti-anxiety compound BNC210 at the annual European College of Neuropsychopharmacology (ECNP) conference in Amsterdam. The data presented demonstrates preclinical and clinical attributes of BNC210 that provide further support for its development for the treatment of anxiety and depression.

The first poster outlines the performance of BNC210 in a rat model of chemically-induced panic. It is well documented that the neurotransmitter, cholecystokinin (CCK), provokes panic attacks in man and provides a model for assessing the efficacy of compounds with the potential to treat anxiety. Diazepam, which is prescribed for the treatment of anxiety and panic disorder, is known to be active in CCK challenge studies. When the two drugs are compared in CCK-treated rats, BNC210 reduced anxiety in a dose dependent manner without sedation, whereas Diazepam produced clear signs of sedation.

Dr Deborah Rathjen, Bionomics' CEO & Managing Director, said she is excited that BNC210 exhibits such potent activity in this preclinical model of panic without displaying sedation which is one of the key side-effects of currently marketed treatments for anxiety. This new data builds on an already impressive body of evidence pointing to the efficacy of BNC210 in a wide range of animal models.

"Based on the results of this study, it is reasonable to suggest that BNC210 may be of therapeutic benefit for panic disorders and other forms of acute anxiety in addition to general anxiety disorder or more chronic forms of anxiety as well as depression" she said.

In the second poster Bionomics presented extensive data on the pharmacokinetics, clinical safety and tolerability of increasing single doses of BNC210 in healthy volunteers, pre and post food intake. The therapeutic window is markedly increased when the drug is given with food. Drug exposure reached a plateau at a 600mg dose in fasted subjects, whereas, when BNC210 was given following a meal, the pharmacokinetics of BNC210 appeared approximately linear up to the highest dose (2000mg). The blood levels observed following a single oral dose of BNC210 were found to exceed the plasma exposure required for efficacy in preclinical models of anxiety and depression. In addition the drug was well tolerated up to the highest dose tested.

BNC210 is about to enter the next stage of clinical development with two Phase Ib clinical trials anticipated to commence shortly.

Both poster presentations are available on Bionomics' website.

Details of the poster exhibits and their respective ECNP abstracts are shown below.

ECNP Amsterdam 2010
Title: Evaluation of the Novel Anxiolytic BNC210 in a Rat Model of Cholecystokinin-Induced Panic.
Poster: P.1.d.021

Title: Evaluation of the Pharmacokinetics and Clinical Tolerability of the Novel Anxiolytic Compound BNC210 in Healthy Volunteers.
Poster: P.4.a.010

FOR FURTHER INFORMATION PLEASE CONTACT:

Bionomics Limited
Dr Deborah Rathjen
CEO & Managing Director
+6I8 8354 6I0I / 04I8 I60 425
drathjen@bionomics.com.au

About Bionomics Limited

Bionomics (ASX: BNO) is a leading international drug discovery and development company. It discovers and develops innovative therapeutics for cancer and diseases of the central nervous system. Bionomics has small molecule product development programs in the areas of cancer, anxiety, epilepsy and multiple sclerosis. BNCI05, which is undergoing clinical development for the treatment of cancer, is based upon the identification of a novel compound that potently and selectively restricts blood flow within tumours. A clinical program is also underway for the treatment of anxiety disorders based on BNC2I0 which exhibits strong anxiolytic activity without side effects in preclinical models. Both compounds offer blockbuster potential if successfully developed.

Bionomics' discovery and development activities are driven by its three technology platforms: Angene®, a drug discovery platform which incorporates a variety of genomics tools to identify and validate novel angiogenesis targets (involved in the formation of new blood vessels). MultiCore® is Bionomics' proprietary, diversity orientated chemistry platform for the discovery of small molecule drugs. ionX® is a set of novel technologies for the identification of drugs targeting ion channels for diseases of the central nervous system.

For more information about Bionomics, visit www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of I995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to the clinical evaluation of either BNCI05 or BNC2I0, our available funds or existing funding arrangements, a downturn in our customers' markets, our failure to introduce new products or technologies in a timely manner, regulatory changes, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantages, as well as other factors. Subject to the requirements of any applicable legislation or the listing rules of any stock exchange on which our securities are quoted, we disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.